Cell Cryopreservation Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product (Cell Freezing Media, Equipment, Consumables), By Application (Stem Cells, Oocytes and Embryotic Cells, Sperm Cells, Hepatocytes, Others), By Region and Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 11.84 Billion
CAGR (2026-2031)	5.73%
Fastest Growing Segment	Cell Freezing Media
Largest Market	North America
Market Size (2031)	USD 16.54 Billion

Market Overview

The Global Cell Cryopreservation Market will grow from USD 11.84 Billion in 2025 to USD 16.54 Billion by 2031 at a 5.73% CAGR. Cell cryopreservation involves the process of cooling biological samples to sub-zero temperatures to suspend metabolic activity and maintain cellular viability for future application. The market expansion is primarily driven by the escalating development of regenerative medicines and the integral role of biobanking in clinical research. Additionally, sustained investment in biopharmaceutical research and development supports long-term growth by necessitating reliable storage solutions for increasingly complex cellular products.

Despite this progress, the high capital and operational expenditures required to maintain cold chain infrastructure present a significant challenge to rapid market scalability. This cost burden is intensified by the growing volume of therapeutic candidates entering development which requires consistent preservation. According to the Alliance for Regenerative Medicine, in 2024, there were 2,406 active clinical trials globally for cell and gene therapies. While this figure indicates strong demand, the financial complexity of preserving such a vast quantity of biological material remains a hurdle for efficient supply chain management.

Key Market Drivers

Rapid Expansion of the Regenerative Medicine and Cell Therapy Landscape drives the market by necessitating robust cold chain infrastructure. As gene-edited therapies transition from clinical development to commercial availability, the requirement for decentralized preservation capabilities grows significantly. This scaling is supported by substantial industry funding intended to accelerate pipeline progression. According to the Alliance for Regenerative Medicine, October 2024, in the 'State of the Industry' presentation, the sector attracted $10.9 billion in investment during the first half of 2024. Consequently, developers are establishing extensive treatment networks to manage patient supply chains. According to Vertex Pharmaceuticals, February 2025, in the 'Fourth Quarter and Full Year 2024 Financial Results', the company had activated more than 50 authorized treatment centers globally by the end of 2024. This operational expansion underscores the increasing reliance on cryopreservation technologies to ensure the viability of autologous products across complex logistical channels.

Surging Prevalence of Infertility and Demand for Assisted Reproductive Technologies (ART) significantly amplifies market momentum, as modern fertility treatments depend heavily on the vitrification of biological samples. The industry is witnessing a shift toward "freeze-all" protocols and elective fertility preservation, creating sustained demand for long-term storage solutions. According to the Society for Assisted Reproductive Technology, April 2025, in the 'National Summary Report', the total number of IVF cycles performed at member clinics increased to 432,641 in 2023. This rising procedural volume directly necessitates advanced cryopreservation media and automated storage systems to maintain the integrity of gametes and embryos over extended durations.

Download Free Sample Report

Key Market Challenges

The high capital and operational expenditures associated with establishing and maintaining cold chain infrastructure pose a substantial barrier to the expansion of the cell cryopreservation market. Implementing robust storage facilities involves significant upfront investment in specialized freezing equipment, automated monitoring systems, and redundant power supplies to ensure sample integrity. These costs extend beyond initial setup, as continuous operational expenses for liquid nitrogen supply, equipment maintenance, and strict regulatory compliance create a persistent financial strain on preservation service providers and biopharmaceutical developers.

This financial pressure is further exacerbated by the sheer volume of biological material that requires secure, long-term retention during the development cycle. As the pipeline of therapeutic candidates expands, the aggregate cost to preserve these sensitive materials increases proportionately, often stretching the limited resources of smaller development firms. According to the American Society of Gene & Cell Therapy, in 2024, the total global pipeline included 4,021 gene, cell, and RNA therapies ranging from preclinical to pre-registration stages. Managing the storage logistics for such an extensive number of developmental assets requires massive capital allocation, which directly restricts the ability of the market to scale operations efficiently.

Key Market Trends

The integration of robotic automation in biobanking workflows is transforming sample management by minimizing human interaction and ensuring consistent temperature stability during handling. As biorepositories face pressure to improve operational efficiency and reduce preservation errors, facilities are deploying automated retrieval systems that maintain sample integrity at ultra-low temperatures without the variability of manual access. This operational shift is evidenced by the growing investment in advanced sample management infrastructure. According to Azenta Life Sciences, May 2025, in the 'Second Quarter Fiscal 2025 Results', revenue from its Sample Management Solutions segment reached $80 million, an 8% increase driven largely by robust demand for automated storage systems and clinical sample management services.

Simultaneously, the market is experiencing a critical transition toward ready-to-use, GMP-compliant cryopreservation media to meet stringent regulatory standards for cell and gene therapies. Developers are moving away from traditional serum-based and home-brew formulations to chemically defined alternatives that offer higher lot-to-lot consistency and reduced toxicity risks. This adoption of optimized biopreservation tools is accelerating as commercial therapies scale manufacturing. According to BioLife Solutions, May 2025, in the 'First Quarter 2025 Financial Results', cell processing revenue increased 33% year-over-year to $21.6 million, a growth attributed primarily to the widespread incorporation of its GMP-grade media into the manufacturing processes of 17 approved commercial therapies.

Segmental Insights

Based on recent data from trusted market research, the Cell Freezing Media segment represents the fastest-growing category within the Global Cell Cryopreservation Market. This rapid expansion is primarily driven by the escalating demand for reliable biopreservation solutions in regenerative medicine and cell-based therapeutics. As the biopharmaceutical industry accelerates the development of novel treatments, there is a critical need for standardized media that ensures optimal post-thaw cell viability. Consequently, market participants are increasingly adopting chemically defined, serum-free, and GMP-compliant formulations to mitigate contamination risks and align with stringent safety guidelines established by regulatory entities like the U.S. Food and Drug Administration.

Regional Insights

North America maintains a dominant position in the global cell cryopreservation market due to robust infrastructure for healthcare and biotechnology research. The region benefits from significant investments in regenerative medicine and drug discovery by both government and private entities. This leadership is further strengthened by the presence of major industry players and an extensive network of biobanks. Additionally, the United States Food and Drug Administration facilitates market growth through streamlined regulatory pathways for cell-based therapies. Consequently, high adoption rates of preservation techniques for stem cells and tissues ensure North America remains the leading regional market.

Recent Developments

• In April 2025, BioLife Solutions completed the acquisition of PanTHERA CryoSolutions, securing full ownership of a developer specializing in novel cryopreservation technologies. The transaction, valued at approximately $9.3 million in cash along with stock, integrated proprietary ice recrystallization inhibitor technology into the acquiring company's portfolio. This technology is designed to control ice crystal formation during the freezing process, thereby reducing cellular damage and improving post-thaw recovery rates. The deal followed a successful multi-year co-development partnership and positions the company to commercialize next-generation preservation media that enhance the stability and efficacy of cell-based therapies.
• In June 2024, Thermo Fisher Scientific opened a new current Good Manufacturing Practice (cGMP) facility in Bleiswijk, Netherlands, to bolster its support for clinical trials across Europe. The site is equipped to provide comprehensive storage solutions ranging from ambient to cryogenic temperatures, directly addressing the critical needs of the cell and gene therapy market. This expansion enables the company to offer end-to-end services, including the packaging, labeling, and distribution of sensitive biological materials. The facility is designed to meet the increasing demand for specialized ultra-cold infrastructure required to maintain the viability of advanced therapeutics during development and commercialization.
• In June 2024, Cryoport, Inc. established a strategic partnership with Minaris Regenerative Medicine to provide integrated logistics and manufacturing services for the life sciences industry. This collaboration leverages the supply chain and temperature-controlled transport capabilities of one company alongside the contract development and manufacturing expertise of the other. The alliance focuses on supporting the regenerative medicine sector by streamlining the handling of cellular products from the initial collection of raw materials to the final delivery of cryopreserved therapies. By combining their resources, the companies aim to ensure the secure and compliant management of sensitive patient treatments on a global scale.
• In May 2024, BioLife Solutions introduced a new rigid container specifically designed for the storage and transport of cell and gene therapies. Launched at an industry conference, this product was engineered to replace traditional cryopreservation bags, which are often susceptible to fractures and particulate contamination during ultra-low temperature storage. The new container features a closed-system design compatible with automated fill and retrieval processes, ensuring sterility and ease of use. By offering a fracture-resistant and transparent alternative, the company aims to improve the integrity and inspection compliance of high-value biologic materials throughout the cold chain.

Key Market Players

• Thermo Fisher Scientific Inc.
• PromoCell GmbH
• Merck KGaA
• Sartorius AG
• Lonza Group Ltd.
• Corning Incorporated
• Creative Biolabs
• BioLife Solutions Inc.
• Danaher Corporation
• HiMedia Laboratories Pvt. Ltd

By Product	By Application	By Region
Cell Freezing Media Equipment Consumables	Stem Cells Oocytes and Embryotic Cells Sperm Cells Hepatocytes Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Cell Cryopreservation Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Cell Cryopreservation Market, By Product:

• Cell Freezing Media
• Equipment
• Consumables

• Cell Cryopreservation Market, By Application:

• Stem Cells
• Oocytes and Embryotic Cells
• Sperm Cells
• Hepatocytes
• Others

• Cell Cryopreservation Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE